FDA clears Langlara, a new interchangeable Lantus biosimilar

Version 1

Lannett, its newly formed U.S. biosimilars unit Lanexa Biologics, and China-based Sunshine Lake Pharma said the FDA has approved Langlara (insulin glargine-aldy) as an interchangeable biosimilar to Sanofi’s Lantus. The product is approved for adults and pediatric patients with type 1 diabetes and for adults with type 2 diabetes, and the companies said they plan to commercialize it in the U.S. through Lanexa. FDA’s biosimilar database lists Langlara as approved in April 2026, making it a new entrant in the long-acting insulin glargine market and another interchangeable option tied to Lantus. (streetinsider.com)

Why it matters: For veterinary professionals, this is a human-drug market development worth watching because shifts in the insulin glargine supply and pricing landscape can ripple into companion animal care, especially for practices managing diabetic cats and dogs and for pet parents facing affordability barriers. Interchangeable status matters at the pharmacy counter because, where state law allows, pharmacists may substitute Langlara for Lantus without contacting the prescriber, which could affect availability, payer coverage, and what product a pet parent is actually dispensed. (streetinsider.com)

What to watch: Watch for launch timing, formulary uptake, and whether added competition in insulin glargine translates into better availability or lower costs in channels that matter to veterinary prescribing and pet parent access. (streetinsider.com)